Evaluation and Management of Thrombocytopenia
For immune thrombocytopenia (ITP), the most critical decision is whether to treat based on bleeding symptoms rather than platelet count alone, with observation recommended for patients without bleeding or with only mild skin manifestations regardless of platelet count. 1
Initial Severity Assessment and Bleeding Risk
The definition of thrombocytopenia is a platelet count <150 × 10⁹/L, though ITP is specifically defined as <100 × 10⁹/L. 1, 2 However, bleeding risk does not correlate linearly with platelet count and must be assessed clinically:
- Platelet count >50 × 10⁹/L: Generally asymptomatic with minimal bleeding risk 2
- Platelet count 20-50 × 10⁹/L: May develop mild skin manifestations (petechiae, purpura, ecchymosis) 2
- Platelet count <10 × 10⁹/L: High risk of serious bleeding 2
- Active hemorrhage or mucosal bleeding: Requires immediate intervention regardless of count 1
Diagnostic Evaluation Algorithm
Step 1: Exclude Pseudothrombocytopenia
In stable outpatients, first collect blood in heparin or sodium citrate tubes and repeat the platelet count to exclude EDTA-induced platelet clumping. 2
Step 2: Determine Acute vs. Chronic
Review previous platelet counts to distinguish acute from chronic thrombocytopenia. Acute thrombocytopenia may require hospitalization. 2
Step 3: Screen for Secondary Causes
Test all patients for HCV and HIV as these are common secondary causes requiring specific management. 1 Consider screening for H. pylori infection, particularly in adults, as eradication therapy can improve platelet counts. 1
Step 4: Bone Marrow Examination
Bone marrow examination is NOT necessary in patients with typical ITP presentation, regardless of age. 1 This includes:
- Children and adolescents with typical ITP features 1
- Adults presenting with isolated thrombocytopenia 1
- Patients who fail IVIg therapy 1
- Prior to corticosteroid initiation or splenectomy 1
Bone marrow examination IS indicated if there are abnormalities beyond thrombocytopenia in the blood count or smear. 1
Management Strategy by Population
Pediatric ITP (Children and Adolescents)
Initial Management
Children with no bleeding or only mild bleeding (skin manifestations like bruising and petechiae) should be managed with observation alone, regardless of platelet count. 1 This is a strong recommendation that prioritizes quality of life over arbitrary platelet thresholds.
For outpatient vs. inpatient management:
- Platelet count <20 × 10⁹/L with no/mild bleeding: Manage as outpatient 3
- Platelet count ≥20 × 10⁹/L with no/mild bleeding: Manage as outpatient 3
- Exceptions: Diagnostic uncertainty, social concerns, distance from hospital, or inability to guarantee follow-up 3
First-Line Treatment (When Required)
When treatment is necessary due to significant bleeding:
- Single dose of IVIg (0.8-1 g/kg) OR short course of corticosteroids 1
- Use IVIg if more rapid platelet increase is needed 1
- Anti-D (single dose) can be used in Rh-positive, non-splenectomized children 1
- Do NOT use anti-D if hemoglobin is decreased from bleeding or if autoimmune hemolysis is present 1
Second-Line Treatment (Persistent/Chronic ITP)
For children with significant ongoing bleeding despite first-line therapy:
- Rituximab may be considered, though response rates are variable (only 8 of 36 patients maintained platelets >50 × 10⁹/L at 1 year in one trial) 1
- High-dose dexamethasone may be considered 1
- Both can serve as alternatives to splenectomy 1
Splenectomy Timing
Splenectomy should be delayed for at least 12 months unless there is severe, unresponsive disease or significant quality of life impairment, due to high spontaneous remission rates. 1 Indications include:
- Significant or persistent bleeding 1
- Lack of response or intolerance to corticosteroids, IVIg, and anti-D 1
- Need for improved quality of life 1
Adult ITP
Treatment Threshold
Treatment should be administered for newly diagnosed patients with platelet count <30 × 10⁹/L. 1 This is a conditional recommendation recognizing that bleeding risk, not just platelet count, drives treatment decisions.
First-Line Treatment
Longer courses of corticosteroids (≤6 weeks including taper) are preferred over shorter courses or IVIg as first-line treatment. 1, 3 Specifically:
- Avoid prolonged courses >6 weeks due to toxicity without additional benefit 3
- Add IVIg (1 g/kg as one-time dose) with corticosteroids when rapid platelet increase is required 1
- Use IVIg or anti-D as first-line if corticosteroids are contraindicated 1
Second-Line Treatment (≥3 Months Duration)
For patients who are corticosteroid-dependent or unresponsive after ≥3 months:
The 2019 ASH guidelines provide a hierarchical approach:
Between TPO-RAs (eltrombopag vs. romiplostim): Either option is acceptable; choice depends on patient preference for daily oral (eltrombopag) vs. weekly subcutaneous (romiplostim) administration 3
Between splenectomy and TPO-RA: Either option is suggested, with choice based on patient values regarding surgery avoidance vs. long-term medication 3
Between rituximab and splenectomy: Rituximab is preferred over splenectomy 3
Between TPO-RA and rituximab: TPO-RA is preferred over rituximab 3
Practical algorithm synthesis: TPO-RA > Rituximab > Splenectomy, though splenectomy remains strongly recommended for patients who have failed corticosteroid therapy and prefer definitive treatment. 1 Splenectomy achieves 70-80% sustained response rates. 1
Splenectomy should ideally be delayed for at least 1 year after diagnosis due to potential for spontaneous remission. 3 Both laparoscopic and open approaches offer similar efficacy. 1
Post-Splenectomy Management
Do NOT treat asymptomatic patients after splenectomy who have platelet counts >30 × 10⁹/L. 1
Special Populations
Pregnancy
Pregnant patients requiring treatment should receive either corticosteroids or IVIg. 1 Mode of delivery should be based on obstetric indications, not maternal platelet count. 1
Secondary ITP
HIV-associated ITP:
- Treat HIV infection with antiviral therapy FIRST unless clinically significant bleeding is present 1
- If ITP treatment needed: corticosteroids, IVIg, or anti-D 1
- Splenectomy preferred over other agents for symptomatic patients failing initial therapy 1
HCV-associated ITP:
- Consider antiviral therapy in absence of contraindications, but monitor platelets closely as interferon can worsen thrombocytopenia 1
- If ITP treatment needed: IVIg is preferred 1
H. pylori-associated ITP:
- Administer eradication therapy if infection confirmed by urea breath test, stool antigen, or endoscopic biopsy 1
Platelet Transfusion Indications
Prophylactic platelet transfusion should be considered:
- Platelet count <10-20 × 10⁹/L in stable patients 4
- Platelet count <50 × 10⁹/L before invasive procedures 2, 4
Do NOT transfuse platelets in:
For active hemorrhage: Transfuse to maintain platelets 50-100 × 10⁹/L depending on bleeding severity. 5
Critical Pitfalls to Avoid
Do not delay treatment in emergent causes: Heparin-induced thrombocytopenia (HIT), thrombotic microangiopathies, and HELLP syndrome require immediate recognition and intervention 2, 4
Recognize paradoxical thrombosis risk: ITP patients, particularly those on TPO-RAs, have increased venous thrombosis risk (cumulative incidence 9.3% at 1 year of TPO-RA exposure) 6. Consider long-term anticoagulation in patients with persistent risk factors.
Ensure pre-splenectomy vaccination: Patients must receive appropriate immunizations and counseling regarding antibiotic prophylaxis before splenectomy 3
Activity restrictions: Patients with platelets <50 × 10⁹/L should avoid trauma-associated activities 2
Avoid treating platelet counts instead of patients: The decision to treat should be based on bleeding symptoms and quality of life impact, not arbitrary platelet thresholds 1, 3